Galecto, Inc. (GLTO)
US — Healthcare Sector
Automate Your Wheel Strategy on GLTO
With Tiblio's Option Bot, you can configure your own wheel strategy including GLTO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GLTO
- Rev/Share 0.0
- Book/Share 10.3698
- PB 0.3153
- Debt/Equity 0.0044
- CurrentRatio 9.6215
- ROIC -1.3167
- MktCap 4324117.0
- FreeCF/Share -11.4417
- PFCF -0.2859
- PE -0.2337
- Debt/Assets 0.0039
- DivYield 0
- ROE -0.9989
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Galecto, Inc. (GLTO)
- IPO Date 2020-10-29
- Website https://galecto.com
- Industry Biotechnology
- CEO Dr. Hans T. Schambye M.D., Ph.D.
- Employees 5
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.